30 years ago, it was realised that nitric oxide was protean and regulates almost every bodily function, including neuronal function important in laying down memories and regulating the tone of muscles in the walls of the coronary artery. Subsequent research into the role of nitric oxide in various diseases was associated with a rapid increase the nitric oxide literature \[[@C1]\]. Nitric oxide is produced by nitric oxide synthetase (NOS), which is a family of enzymes \[[@C1]\]. Briefly, NOS can be considered as having two isoforms: constitutive (cNOS), which constantly produces relatively small quantities of nitric oxide; and inducible (iNOS), which responds to various stimuli and is able to quickly produce large quantities of nitric oxide. iNOS is considered more important than cNOS to various diseases, including those of the respiratory system.

Why might exhaled nitric oxide fraction be a useful marker of respiratory disease? {#s4}
==================================================================================

In the respiratory tract, nitric oxide is produced by a variety of structural and inflammatory cells, including eosinophils, macrophages, epithelial cells and smooth muscle cells \[[@C2]\]. During inflammation, the concentration of nitric oxide increases in the lungs and nitric oxide can be measured in the exhaled breath as the exhaled nitric oxide fraction (*F*~ENO~). Elevated *F*~ENO~ levels generally reflect eosinophilic airway inflammation \[[@C2]\] and patients likely to benefit from corticosteroids \[[@C2]\]; monitoring levels of eosinophilic airway inflammation using *F*~ENO~ as a noninvasive surrogate should theoretically aid clinical management \[[@C2], [@C3]\]. In the current era, in which we aspire to personalised medicine \[[@C4]\], *F*~ENO~ may be crucial to categorising asthma pheno/endotypes, although these is remain to be determined. This review explores the current thinking of how *F*~ENO~ should be applied in the respiratory clinical setting, and focuses on the potential role of *F*~ENO~ in diagnosing and monitoring asthma and COPD.

Currently, in the clinical setting, eosinophilia can be defined in blood, lower airway cells (from sputum or bronchoalveolar lavage) and *F*~ENO~ levels \[[@C5]\]. As recently highlighted, these measures do not always correlate in children, especially in young children \[[@C5]\]. In children with stable asthma, induced sputum eosinophil counts vary over time and have a variable relationship with *F*~ENO~ levels, with discordant values in 25% of paired sputum--*F*~ENO~ measurements \[[@C6]\]. Furthermore, induced sputum-based phenotypes \[[@C7]\] vary considerably in the same individual over time in mild--moderate and severe asthma in children. Nevertheless, measuring *F*~ENO~ levels is increasingly available and advocated. As it adds an additional cost of ∼US\$8.50 per test (which equates to ∼US\$17.00 per occasion, excluding the cost of labour) above current universal practice \[[@C2]\], evidence for its application in routine clinical practice requires evaluation.

How is *F*~ENO~ measured? {#s5}
=========================

Nasal and exhaled breath nitric oxide can be measured using widely available nitric oxide analysers. Nasal nitric oxide is not used for asthma or COPD-related diagnosis or monitoring and hence, this article is restricted to *F*~ENO~.

Like other lung function tests, standardised methods of measuring *F*~ENO~ need to be adhered to for reliable results \[[@C2]\]. The online test is simple, requiring the individual to exhale to reach an acceptable plateau with online visual feedback and tests are performed at least twice to achieve results within 10% of each other \[[@C2]\]. With the wide availability of portable *F*~ENO~ analysers, the offline method, where breath was collected in a bag and then, at a later stage, taken to a machine and analysed, is now not used in the clinical setting

*F*~ENO~ levels provided by nitric oxide analysers are not equivalent, with differences as large as 30% \[[@C8]\]. A study comparing *F*~ENO~ levels measured by NIOX VERO (Aerocrine AB, Solna, Sweden) described significantly lower values than that measured with the NOA280i (Sievers Instruments, Boulder, CO, USA), where the median values were 29 parts per billion (ppb) and 41 ppb respectively \[[@C8]\], *i.e.* the portable NIOX values were 30% lower than the standard chemiluminescence stationary electrochemical analyser; and between portable *F*~ENO~ analysers, there was variability among devices (limits of agreement is up to 10 ppb) \[[@C9]\]. Portable *F*~ENO~ analysers have cartridges which need changing after a preset number of measurements are made, and different cartridges can deliver slightly different *F*~ENO~ concentrations when the same patient uses the same analyser.

Factors other than asthma that affect *F*~ENO~ {#s6}
==============================================

*F*~ENO~ levels are affected by various external factors \[[@C2]\] (*e.g.* nitric oxide analyser variability, air pollutants, season and ambient nitric oxide). In addition to the external factors, clinicians need to be cognisant of the many factors that influence these levels above and beyond clinical disease when using and/or interpreting studies involving *F*~ENO~ and its levels in patients \[[@C10]\]. Atopy is an important factor that is associated with elevated *F*~ENO~ independent of asthma. Other factors include ethnicity, height, age, recent dietary intake, exercise and tobacco exposure. Inhaled corticosteroids (ICS) and leukotriene receptor antagonists both lower *F*~ENO~ \[[@C2]\]. Interestingly, age is the only factor that many guidelines suggest should be considered when interpreting *F*~ENO~ \[[@C2], [@C9]\].

Interpretation of *F*~ENO~ {#s7}
==========================

*F*~ENO~ can be interpreted in at one of at least three ways: As a percentage of the predicted value for the population, but this is not a preferred method \[[@C2]\], in part due to a lack of data and in part due to the many factors (previously discussed) that may affect *F*~ENO~ independent of asthma.As a single "one-size fits all" cut-off value, and this is currently the preferred value \[[@C2]\] although there are some limitations to this including the low values in people with nonatopic asthma and individuals with values close to a single cut-off may find their treatment varies as *F*~ENO~ values fall just above or just below the threshold concentration.As a use percentage change from a previous value, and this may have merit for monitoring of asthma over time \[[@C2]\].Currently, *F*~ENO~ results are classified as either normal, intermediate or abnormal positive for diagnostic of eosinophilic airway inflammation (note that this is not diagnostic of asthma). *F*~ENO~ values below the reference (cut-offs) indicate a likely absence of eosinophilic inflammation and a lower likelihood of response to corticosteroids \[[@C2]\]. Importantly, these statements are acknowledged to be based on low-quality evidence \[[@C2]\] and several guidelines interpret the available literature in different ways an recommend different cut-offs in adults and children \[[@C2], [@C9], [@C11], [@C12]\] ([table 1](#TB1){ref-type="table"}). Table 1A summary of the recommended *F*~ENO~ cut-off values for use in asthma diagnosis and management from international guidelines**Age range for children yearsHealthy values ppbIntermediate values ppbElevated values ppbRecommended role of *F*~ENO~ in diagnosing asthmaRecommended role of *F*~ENO~ in diagnosing asthmaChildrenAdultsChildrenAdultsChildrenAdultsATS (2011) \[2\]**\<12\<20\<2520--3525--50\>35\>50*F*~ENO~ may be used to support the diagnosis of asthma in situations in which objective evidence is needed.The use of *F*~ENO~ in monitoring airway inﬂammation in patients with asthma is recommended**National Institute for Health and Care Excellence (2017) \[9\]**5--16Not statedNot statedNot statedNot stated\>35\>40Diagnose asthma if patients have symptoms suggestive of asthma, an elevated *F*~ENO~, positive peak flow variability or obstructive spirometry, and positive bronchodilator reversibilityDo not routinely use *F*~ENO~ use to monitor asthma control**GINA (2019) \[11\]**6--11Not statedNot statedNot statedNot stated\>50\>50*F*~ENO~ has not been established for ruling in or ruling out a diagnosis of asthma*F*~ENO~-guided treatment is not recommended for the general population\
There may be a role for *F*~ENO~ in a severe asthma clinic; cut-offs of 20, 25 and 50 ppb may have a role in stratifying treatment**British Thoracic Society/Scottish Intercollegiate Guidelines (2019) \[12\]**5--16\>35\>40Use measurement of *F*~ENO~ (if available) to find evidence of eosinophilic inflammation\
A positive test increases the probability of asthma but a negative test does not exclude asthmaExcept in specialist asthma clinics, the routine use of *F*~ENO~ testing to monitor asthma in adults or children is not recommended

Exhaled nitric oxide in childhood asthma {#s8}
========================================

Feasibility {#s8a}
-----------

*F*~ENO~ can be measured using commercially available equipment in most children aged ≥6 years and values are reproducible over a 24-h period \[[@C13]\]. Unfortunately, at present, although the challenge of diagnosing asthma and the overall burden of asthma symptoms is in children aged 5 years and younger, *F*~ENO~ cannot be measured outside of research setting in this age group.

*F*~ENO~ and asthma diagnosis {#s8b}
-----------------------------

Epidemiological papers published since 1997 \[[@C14]\] that have described elevated *F*~ENO~ in children with asthma compared individuals with established asthma to controls. Although these studies provided proof of the concept that *F*~ENO~ may be useful in diagnosing asthma, they do not provide valid cut-off *F*~ENO~ values for asthma diagnosis. Comparing differences in *F*~ENO~ between groups who have "typical" asthma and controls does not help in the clinical encounter with a child who may have asthma. The absence of a gold standard diagnostic test for asthma also gives researchers a challenge in establishing the role of *F*~ENO~ in diagnosing asthma.

There have been at least four studies that measured *F*~ENO~ in children being considered for a diagnosis of asthma as part of observational, "real-life" asthma diagnosis programmes in hospital clinics \[[@C15]--[@C18]\]. These studies identified *F*~ENO~ cut offs of between 16 and 22 ppb as having the best combination of sensitivity and specificity for a later asthma diagnosis. An important confounder for interpreting *F*~ENO~ in the context of asthma diagnosis is prior asthma treatment since both ICS \[[@C19]\] and leukotriene receptor antagonists \[[@C20]\] reduce *F*~ENO~ by up to one third. The study with the highest cut-off was the only one to include only steroid-naïve children \[[@C16]\], whereas other studies included 11% \[[@C18]\] to 33% \[[@C15]\] on ICS or children who had their ICS withheld for 4 weeks \[[@C17]\].

As previously described, there is uncertainty about which precise cut-off value should be applied to asthma diagnosis in children but despite their limitations, these four studies would support a cut off value of 15--20 ppb for diagnosing asthma. A key question for clinicians to consider after having taken a history and then measuring *F*~ENO~ is whether they believe an asthma diagnosis is likely or not; if the history suggests that asthma is likely then a *F*~ENO~ value \>15 ppb could be supportive of a diagnosis and if asthma seems unlikely, then a *F*~ENO~ value \<20 ppb would be helpful in excluding an asthma diagnosis. Two European Respiratory Society task forces are currently exploring, from different perspectives, the role of *F*~ENO~ in diagnosing childhood asthma and, collectively, will bring more clarity to clinicians in this area.

*F*~ENO~ and monitoring childhood asthma {#s8c}
----------------------------------------

In principle, *F*~ENO~ offers everything that an objective test should have for monitoring asthma in children since it has the following characteristics: sensitivity to symptomssensitivity to treatmenta known biomarker for airway eosinophiliareproducibilityresults are available almost immediatelyapparatus is portable and affordable

Not surprisingly, at least eight clinical trials \[[@C10]\] have evaluated the role of *F*~ENO~ in guiding treatment to reduce asthma exacerbations and improve asthma control. There were important differences between these trials in several aspects, as described elsewhere \[[@C10]\], summarised in [table 2](#TB2){ref-type="table"} and discussed here. Inclusion criteria: atopy is a key determinant of *F*~ENO~ and four trials selected only participants who were atopic; by including a mix of participants, it is not surprising that the results were heterogeneous.Primary outcomes: the primary outcome determines a study sample size, and such outcomes include exacerbations, control (as evidenced by a symptom score) and change in lung function; the presence of different primary outcomes makes it hard to directly compare results between studies.Population size: this varied between 47 and 546 with a median of 88 participants; many trials are likely to have been underpowered and reported false-negative findings.*F*~ENO~ values used to trigger treatment changes: the trials were published between 2005 and 2015, and during this decade, our understanding of *F*~ENO~ changed. It was increasingly recognised that *F*~ENO~ behaves differently to percentage of predicted forced expiratory volume in 1 s (FEV~1~); for example, *F*~ENO~ is much more variable than FEV~1~ % pred and worse asthma outcomes are associated with increasing *F*~ENO~ but falling FEV~1~ % pred. The earlier studies used a single *F*~ENO~ value to trigger changes in treatment whereas some later studies had a "sliding scale" and used two or more values, and one had different values for nonatopic and atopic children. The pioneering trials may have been too simplistic when applying *F*~ENO~ to treatment.Inclusion of FEV~1~: three trials used a cut-off of FEV~1~ \<80% pred to influence treatment decisions in addition to rising *F*~ENO~ values. This means that decision making in these trials was not solely influenced by *F*~ENO~.Treatment changes made: studies had different treatment steps triggered by different *F*~ENO~ cut-offs. Some studies only changed ICS dose and different dose changes were applied.

###### 

Characteristics of trials that have used *F*~ENO~ to guide treatment in children with asthma

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **First author \[ref.\]**                                   **Primary outcome(s)**                    **Mean age^\#^ years**   **Participants**   **Atopy as inclusion criterion?**   **FEV~1~ \<80% pred also used in treatment algorithm?**   ***F*~ENO~ cut-off(s) used ppb**                      **What did the trial find? (*F*~ENO~ treatment compared to standard care)**
  ----------------------------------------------------------- ----------------------------------------- ------------------------ ------------------ ----------------------------------- --------------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------------------------------
  **F[ritsch]{.smallcaps} \[21\]**                            FEV~1~                                    11.5                     47                 Yes                                 Yes                                                       20                                                    Higher midexpiratory flow, higher dose of ICS

  **P[eirsman]{.smallcaps} \[22\]**                           Symptom-free days                         11                       99                 Yes                                 Yes                                                       20                                                    Reduced exacerbations, increased LTRA and ICS dose\
                                                                                                                                                                                                                                                                                                        No difference in primary outcome

  **P[etsky]{.smallcaps} \[23\]**                             Exacerbations                             10                       63                 No                                  No                                                        10 for nonatopic, 12 with one PSPT, 20 for \>1 PSPT   Reduced exacerbation, increased ICS dose

  **P[ijnenburg]{.smallcaps} \[24\]**                         Cumulative ICS dose                       12                       84                 No                                  No                                                        30                                                    Reduced *F*~ENO~ and bronchial hyperresponsiveness\
                                                                                                                                                                                                                                                                                                        No increase in ICS dose

  **P[ike]{.smallcaps} \[25\]**                               ICS dose and exacerbation frequency       11                       90                 No                                  No                                                        ≤15 and ≥25                                           No differences in outcomes

  **S[zefler]{.smallcaps} \[26\]**                            Days with asthma symptoms                 14                       546                Yes                                 Yes                                                       20, 30 and 40                                         Reduced exacerbations, increased ICS dose\
                                                                                                                                                                                                                                                                                                        No difference in primary outcome.

  **V[erini]{.smallcaps} \[27\]**                             Exacerbations, symptom score, treatment   12                       64                 No                                  No                                                        12                                                    Reduced exacerbations, improved symptom score, less asthma treatment

  **V[oorend-van]{.smallcaps} B[ergen]{.smallcaps} \[28\]**   Proportion of symptom-free days           10                       181^¶^             Yes                                 No                                                        20 and 50                                             Increased asthma control but not the primary outcome
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PSPT: positive skin-prick test; LTRA: leukotriene receptor antagonist. ^\#^: where mean age is given for children in separate arms of trial, an approximate overall mean age is given; ^¶^: not including 91 randomised to a web-based intervention.

Despite these considerable differences, these trials collectively provide evidence that asthma treatment guided by *F*~ENO~ reduces the risk of asthma attacks \[[@C10], [@C29]\] and the mechanism for this might be due to an increased in ICS \[[@C10]\]. There is no evidence that asthma control (a primary outcome in many studies) was improved in these trials \[[@C29]\], and it is increasingly recognised that there are different factors driving asthma control compared to exacerbations \[[@C30]\]. Despite providing proof of the concept that *F*~ENO~ has a role in managing childhood asthma, the differences between the trials mean that there is considerable uncertainty as to how *F*~ENO~ can be applied to clinical practice.

The answer to question "when should *F*~ENO~ trigger a change in asthma treatment?" is still far from clear, and probably depends on whether the outcome is asthma control or exacerbations. A very cautious recommendation in the American Thoracic Society (ATS) guideline states "We suggest using the following values to determine a significant increase in *F*~ENO~: greater than 20% for values over 50 ppb or more than 10 ppb for values lower than 50 ppb from one visit to the next" \[[@C2]\].

At present, *F*~ENO~ is considered a useful tool in diagnosing asthma in children (or symptoms that are responsive to treatment with corticosteroids) \[[@C2], [@C9]\]. In the absence of robust evidence that links a certain change in *F*~ENO~ to a certain change in treatment to an improved asthma outcome (exacerbation or control), *F*~ENO~ is not recommended for monitoring asthma in all children \[[@C9], [@C12]\]. Looking forward, the absence of evidence for the potential benefit of *F*~ENO~ to diagnose and monitor asthma needs to be addressed by our community. We are hopefully about to step into an era where objective measurements such as FEV~1~ and *F*~ENO~ are used to stratify treatment (perhaps alongside objective measurements of treatment adherence) with the goal of improving symptoms, reducing exacerbation and reducing treatment.

Exhaled nitric oxide in adult respiratory medicine {#s9}
==================================================

*F*~ENO~ in adults with asthma {#s9a}
------------------------------

The ATS guideline outlines potential uses for *F*~ENO~ in adults with asthma, including identifying eosinophilic airway inflammation, predicting responsiveness to ICS, monitoring airway inflammation and detecting nonadherence to ICS \[[@C2]\]. Since the publication of these guidelines in 2011, additional studies have shed further light on the utility of *F*~ENO~ testing in clinical practice.

Is *F*~ENO~ useful for the diagnosis of asthma in adults? {#s9b}
---------------------------------------------------------

Asthma remains a clinical diagnosis in adults supported by evidence of variable airflow limitation, so supplementary testing may be useful for increasing the diagnostic probability of asthma in people who present with variable respiratory symptoms. In a systematic review of the use of *F*~ENO~ for the diagnosis of asthma in adults, *F*~ENO~ ≥40 ppb had a sensitivity of only 41% but a high specificity of 93%, with likelihood ratio for a positive test (high *F*~ENO~) of 6.18 (95% CI 3.64--10.47) \[[@C31]\]. Overall, there was evidence for moderate accuracy for the diagnosis of asthma in adults (*i.e.* a high *F*~ENO~ can rule in asthma but may not be able to rule out asthma).

*F*~ENO~ and asthma phenotypes {#s9c}
------------------------------

Elevated *F*~ENO~ correlates with the presence of specific asthma phenotypes. Consequently, *F*~ENO~ testing may be useful to characterise treatable traits in asthma.

### Sputum eosinophilia {#s9c1}

Eosinophilic airway inflammation is an asthma phenotype that is more likely to be steroid responsive. Biomarkers to predict sputum eosinophilia were evaluated in a study of 336 adults with asthma in the Netherlands. The area under the curve for *F*~ENO~ was 0.82, compared with 0.83 for blood eosinophils and 0.69 for total serum IgE. Hence, *F*~ENO~ and blood eosinophils were similar in accuracy (and more accurate than IgE) for predicting sputum eosinophilia. Furthermore, in a prospective study of 144 adult patients with asthma in Denmark, high *F*~ENO~ (\>50 ppb) had moderate positive predictive value (77%) for sputum eosinophilia of \>3%, although one-third of patients with sputum eosinophilia \>3% had intermediate *F*~ENO~ values (25--50 ppb) \[[@C32]\].

### Cough-variant asthma {#s9c2}

This asthma phenotype is represented by chronic cough, rather than wheeze or breathlessness, and often characterised by type 2 inflammation. *F*~ENO~ has moderate, but not high, accuracy for detection of cough-variant asthma.

### Nonspecific respiratory symptoms {#s9c3}

In primary care, patients may present with symptoms resembling asthma but not meet the clinical criteria for asthma and not have a previous diagnosis of asthma, presenting a diagnostic challenge. *F*~ENO~ could add to the diagnostic testing for these patients. In a randomised controlled trial (RCT) in the UK and Singapore, 517 patients with nonspecific respiratory symptoms, but without a prior history of asthma or bronchodilator reversibility, were randomised to inhaled beclomethasone *versus* placebo for 4 weeks \[[@C33]\]. In the per-protocol analysis (214 patients), those with a greater baseline *F*~ENO~ had a higher improvement in asthma symptoms when on inhaled steroids, compared to the placebo group, as well as reduced cough and improved FEV~1~. As a simple and noninvasive tool, *F*~ENO~ measurement may be helpful for clinical decision making in primary care about whether to trial an ICS in patients with asthma-like symptoms who do not initially meet bronchodilator reversibility and other criteria.

Is *F*~ENO~ useful for the management of asthma in adults? {#s9d}
----------------------------------------------------------

Current asthma clinical guidelines recommend assessment and monitoring of symptoms, exacerbations and lung function tests to optimise asthma management in individual patients. Whether routinely adding measurements of type 2 inflammation is beneficial, beyond clinical and physiological assessment, is still a matter of intense debate.

A Cochrane systematic review examined the benefits of tailored asthma management using *F*~ENO~ levels for adults with asthma, compared with symptom- or guideline-based approaches \[[@C34]\]. Seven studies of 1700 patients were reviewed. Meta-analysis demonstrated a reduction in the number of patients with one or more exacerbations in the *F*~ENO~-guided approach (OR 0.60, 95% CI 0.43--0.84; moderate quality of evidence), translating to a number needed to treat to benefit over 52 weeks of 12 (95% CI 8--32). In contrast, there were no differences in other outcomes such as rates of hospitalisation, symptom scores, *F*~ENO~ levels or ICS dose. The authors\' conclusions were that widespread *F*~ENO~ use for adults with asthma could not be recommended; however, this approach may be useful in patients with more frequent exacerbations. Management based on sputum analysis of airway eosinophilia similarly reduces exacerbations but does not improve asthma control or spirometric measures.

Role of *F*~ENO~ in patients with severe asthma {#s9e}
-----------------------------------------------

*F*~ENO~ testing may have a useful role in severe asthma clinics, where additional asthma phenotyping is helpful for risk stratification and tailored management. In a study of 132 adults with severe allergic asthma in Italy, patients with *F*~ENO~ ≥30 ppb had worse asthma symptoms and quality of life, and higher rates of hospital admission, than patients with *F*~ENO~ \<30 ppb \[[@C35]\].

Oral corticosteroid (OCS)-dependent patients with severe asthma require further treatment choices for better asthma control. The question arises as to how responsive biomarkers are in these patients, especially given chronic OCS use.  *F*~ENO~ responds to a 7-day course of oral prednisolone, and then this and other biomarkers (blood eosinophils, periostin, interleukin (IL)-5 and IL-13) return to baseline by 1 month after an oral steroid burst.

*F*~ENO~ may be responsive to treatment with some biologic agents in severe asthma.

### Omalizumab {#s9e1}

In a subgroup analysis (n=394) of an RCT, patients receiving the anti-IgE monoclonal antibody omalizumab had a small reduction of *F*~ENO~ (mean change --4 ppb) compared to those receiving placebo \[[@C36]\], but reduction in exacerbation rates was much greater in the high-*F*~ENO~ group receiving omalizumab than in the low-*F*~ENO~ group \[[@C37]\]. *F*~ENO~ levels (high (≥25 ppb) *versus* low (\<25 ppb)) do not appear to predict responders to omalizumab.

### Mepolizumab {#s9e2}

There was no statistically significant change in *F*~ENO~ with use of mepolizumab, an anti-IL-5 monoclonal antibody for severe eosinophilic asthma, despite a substantial reduction in blood eosinophil counts.

### Lebrikizumab {#s9e3}

Use of lebrikizumab, an anti-IL-13 monoclonal antibody, reduced *F*~ENO~ by 19% at week 12, compared to a reduction of 10% with placebo \[[@C38]\], consistent with the role of IL-13 in nitric oxide production in the airways.

### Dupilumab {#s9e4}

Dupilumab, an anti-IL-4 and anti-IL-13 monoclonal antibody, reduces *F*~ENO~, compared to placebo, and a greater reduction in exacerbations occurs with baseline *F*~ENO~ ≥25 than \<25 ppb.

Clinical recommendations regarding *F*~ENO~ in adults with asthma {#s9f}
-----------------------------------------------------------------

The 2017 UK National Institute for Health and Care Excellence guidelines for asthma recommend use of *F*~ENO~ testing in adults with asthma \[[@C9]\]. In contrast, the 2019 Global Strategy for Asthma Management and Prevention \[[@C11]\] from the Global Initiative for Asthma (GINA) does not currently recommend *F*~ENO~-guided treatment for all adults with asthma. The GINA strategy notes that elevated *F*~ENO~ can be used to guide initiation of ICS in adults with asthma, but that ICS should not necessarily be withheld in patients with suspected asthma despite a low initial *F*~ENO~ measurement. The GINA strategy also suggests that *F*~ENO~ can be used in adult patients with moderate to severe asthma, in experienced severe asthma centres, as a potential biomarker to predict response to certain biologics.

Future developments {#s9g}
-------------------

Further definition of the clinical utility of *F*~ENO~ in a range of mild, moderate and severe asthma phenotypes should be undertaken in large prospective studies. In addition, characterisation of interacting clinical and biological factors on *F*~ENO~ levels should be undertaken, including the role of the lung microbiome in influencing *F*~ENO~. Comparative studies are needed to test novel molecular biomarkers such as sputum gene expression as predictors of asthma outcomes \[[@C39]\] compared to *F*~ENO~ and other inflammatory markers. Remote, web-based monitoring of suppression of *F*~ENO~ with ICS treatment may improve adherence issues in patients with severe asthma.

*F*~ENO~ in adults with COPD {#s9h}
----------------------------

### Role of *F*~ENO~ in patients with COPD {#s9h1}

Some patients with COPD may have type 2 inflammation, which increases during exacerbations. Furthermore, increased blood eosinophils may predict ICS-responsiveness in patients with COPD; hence, there has been some interest in using *F*~ENO~ to characterise COPD phenotypes.

#### COPD *versus* non-COPD controls {#s9h1a}

Patients with COPD may have a mildly elevated *F*~ENO~ compared to non-COPD, healthy controls.

#### Frequent exacerbators {#s9h1b}

*F*~ENO~ was used to predict frequency of exacerbations in 226 stable COPD patients in Spain. Patients with *F*~ENO~ consistently ≥20 ppb over a 12-month period had a greater risk of exacerbations \[[@C40]\].

#### Exacerbations {#s9h1c}

In a study of 163 patients during a COPD exacerbation, elevated *F*~ENO~ was associated with higher sputum and blood eosinophil levels, although the sensitivity and specificity of *F*~ENO~ were relatively low for sputum eosinophilia (sensitivity 65% and specificity 56% for sputum eosinophilia with *F*~ENO~ ≥17.5 ppb) \[[@C41]\].

#### Hospitalisations {#s9h1d}

In a cohort study of 50 patients hospitalised with a COPD exacerbation, patients with asthma--COPD overlap had higher *F*~ENO~ levels than other COPD phenotypes. *F*~ENO~ correlated with blood eosinophils at admission, but not when measured at discharge or stability \[[@C42]\].

#### Response to ICS treatment {#s9h1e}

A systematic review of five studies of 171 patients with COPD found a decrease in *F*~ENO~ in patients treated with ICS, predominantly in former smokers \[[@C43]\]. COPD patients with high *F*~ENO~ (defined as ≥25 ppb), when given ICS/long-acting β~2~-agonists, had the greatest reduction in *F*~ENO~ and largest improvement in COPD Assessment Test score, compared to those receiving long-acting muscarinic antagonists or low-*F*~ENO~ patients \[[@C44]\].

### Asthma--COPD overlap {#s9h2}

Patients with COPD may have features of asthma such bronchodilator reversibility and eosinophilia. In 80 patients with severe COPD (Global Initiative for Chronic Obstructive Lung Disease grade 4, group D) in Germany, 33% had *F*~ENO~ ≥22.5 ppb \[[@C45]\]. In a study of 121 patients with COPD in Japan, *F*~ENO~ was higher in patients with features of asthma--COPD overlap (median 24.5 ppb) than in patients with COPD (median 16.0 ppb) \[[@C46]\]. When combined with blood eosinophil count, a *F*~ENO~ level of ≥25 ppb, when combined with blood eosinophil count ≥250 per μL, had 96% specificity for asthma--COPD overlap.

Clinical recommendations regarding *F*~ENO~ in COPD {#s9i}
---------------------------------------------------

*F*~ENO~ testing is not routinely recommended in international or national clinical guidelines for patients with COPD alone. However, COPD patients may, at times, have some features of asthma, or some patients may have coexisting asthma and COPD (asthma--COPD overlap), when *F*~ENO~ may be more useful to identify a potential asthma component, as a treatable trait.

Future *F*~ENO~ research in adults and children {#s10}
===============================================

There is currently an absence of evidence for clinicians to confidently apply *F*~ENO~ into routine clinical practice. There are many chronic noncommunicable diseases where there is a "standalone" test for diagnosis and monitoring (*e.g.* blood pressure for hypertension and blood glucose for diabetes) but currently, *F*~ENO~ is not likely to be a standalone test for airway disease. Instead, *F*~ENO~ is likely to be part of an overall evaluation of symptoms and objective measurements for the diagnosis and stratification of treatment for airway disease.

Self-assessment questions
-------------------------

1\) In adult patients with asthma, which one of the following statements is true?

1.  a\. A low *F*~ENO~ level can rule out asthma.

2.  b\. All adult patients with asthma and sputum eosinophilia have high *F*~ENO~ \>50 ppb.

3.  c\. All biologic agents for asthma significantly reduce *F*~ENO~ levels.

4.  d\. *F*~ENO~ testing in adults with asthma leads to a reduction in rates of hospitalisation.

5.  e\. Patients with nonspecific respiratory symptoms and high *F*~ENO~ may show clinical response to ICS.

2)In patients with COPD, for which of the following could *F*~ENO~ testing potentially be useful for?

1.  a\. Detecting type I inflammation in COPD airways.

2.  b\. Diagnosing severe emphysema.

3.  c\. Diagnosing viral exacerbations.

4.  d\. Identifying great likelihood of asthma--COPD overlap.

5.  e\. Predicting response to long-acting bronchodilators.

3)Increased *F*~ENO~ levels occur in all the following situations [except]{.ul}?

1.  a\. Child with allergic rhinitis

2.  b\. Post-exertion.

3.  c\. Diagnosing respiratory viral exacerbations.

4.  d\. During an infection.

5.  e\. African Americans.

4)In children, for which of the following is *F*~ENO~ clinically useful?

1.  a\. Screening for asthma

2.  b\. Definitive diagnoses of asthma

3.  c\. Predicting risk of future exacerbation

4.  d\. Predicting airway obstruction

5.  e\. Monitoring asthma in a small subset of children with asthma

Suggested answers
-----------------

1.  1\) e.

2.  2\) d.

3.  3\) d.

4.  4\) e.
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